Monitoring for potential inflammatory events following intravitreal anti-vascular endothelial factor (VEGF) injection is crucial with the use of new agents such as aflibercept 8 mg. Despite a safety profile co…
Visionary News & Insightful Strategy
Footer
A RETINA-SPECIFIC ORGANIZATION
It’s clearly an advantage to work with a consulting group that’s focused on your industry. The team at Retina Consultant has over 50 years of retina-specific experience in healthcare business, practice management, marketing & operations.
We’ve got our eyes on working with the best retina groups and vendors in the industry.
See the best; get in touch.
Recent
- 4DMT refocuses pipeline to prioritize 4D-150 trials in wet AMD and DME
- FDA approves Zeiss MEL 90 excimer laser
- 4D-150 for DME moving to phase 3 trial following positive interim data
- Formycon partners with Teva, Klinge Biopharma for commercialization of aflibercept biosimilar FYB203 (AHZANTIVE)
- Bausch + Lomb acquires Whitecap Biosciences
Leave a Reply